Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial

Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial

Abstract Background Stereotactic ablative radiotherapy (SABR) has emerged as a new treatment option for patients with oligometastatic disease. SABR delivers precise, high-dose, hypofractionated radiotherapy, and achieves excellent rates of local control for primary tumors or metastases. A recent ran...

Full description

Bibliographic Details
Main Authors: David A. Palma, Robert Olson, Stephen Harrow, Rohann J. M. Correa, Famke Schneiders, Cornelis J. A. Haasbeek, George B. Rodrigues, Michael Lock, Brian P. Yaremko, Glenn S. Bauman, Belal Ahmad, Devin Schellenberg, Mitchell Liu, Stewart Gaede, Joanna Laba, Liam Mulroy, Sashendra Senthi, Alexander V. Louie, Anand Swaminath, Anthony Chalmers, Andrew Warner, Ben J. Slotman, Tanja D. de Gruijl, Alison Allan, Suresh Senan
Format: Article
Language:English
Published: BMC 2019-08-01
Series:BMC Cancer
Subjects:
Oligometastases
Stereotactic radiotherapy
Quality of life
Cancer
Survival
Online Access:http://link.springer.com/article/10.1186/s12885-019-5977-6

Internet

http://link.springer.com/article/10.1186/s12885-019-5977-6

Similar Items